An enhanced expression of human epidermal growth factor receptor 2 (HER2, ErbB2) often occurs in an advanced stage of breast, ovarian, gastric or esophageal cancer, and pancreatic ductal adenocarcinoma (PDAC). Commonly, HER2 expression is associated with poor clinical outcome or chemoresistance in ovarian and breast cancer patients. Treatment with humanized anti-HER2 monoclonal antibodies, such as trastuzumab or pertuzumab, has improved the outcome of patients with HER2-positive metastatic gastric or breast cancer, but not all patients benefit. In this study, the bispecific antibody [(HER2)2xCD16] in the tribody format was employed to re-direct CD16-expressing γδ T lymphocytes as well as natural killer (NK) malignancies. A major advantage of γδ T cells and NK cells in the transplant situation of refractory hematological malignancies is given by their HLA-independent killing and a reduced graft-versus-host disease.
An enhanced expression of human epidermal growth factor receptor 2 (HER2, ErbB2) often occurs in an advanced stage of breast, ovarian, gastric or esophageal cancer, and pancreatic ductal adenocarcinoma (PDAC). Commonly, HER2 expression is associated with poor clinical outcome or chemoresistance in ovarian and breast cancer patients. Treatment with humanized anti-HER2 monoclonal antibodies, such as trastuzumab or pertuzumab, has improved the outcome of patients with HER2-positive metastatic gastric or breast cancer, but not all patients benefit. In this study, the bispecific antibody [(HER2)2xCD16] in the tribody format was employed to re-direct CD16-expressing γδ T lymphocytes as well as natural killer (NK) The human epidermal growth factor receptor 2 [(HER2), ErbB2] stimulates tumor cell proliferation via the Ras-MAP-kinase pathway and its expression is often associated with an aggressive tumor phenotype, advanced stage diseases, and poor clinical outcome (1, 2) . Since anti-HER2 therapies are successful for the treatment of HER2-expressing tumors, HER2 is often selected as a tumor target antigen (3) . HER2 expression in cardiomyocytes does not exclude an anti-HER2 therapy when the cardiac function in patients receiving anti-HER2 therapy is closely monitored. A dysfunction of cardiomyocytes, which is induced in 4% of the cancer patients receiving anti-HER2 therapy, is reversible (4) . However, several HER2-positive tumors are resistant against anti-HER2 therapy or develop a resistance often accompanied by loss of anti-HER2-directed Th1 immunity (5) . In an attempt to optimize anti-HER2 therapies, the initial monotherapy with humanized anti-HER2 mAb trastuzumab (Herceptin ® , Genentech, South San Francisco, CA, USA) against metastatic gastric or breast cancer was gradually replaced by combination therapies with cytostatic agents (e.g., docetaxel, capecitabine, paclitaxel) and/or other anti-HER2 mAb (e.g., pertuzumab), and/or tyrosine kinase inhibitors (e.g., lapatinib) (2, 3, (6) (7) (8) (9) (10) (11) (12) . Alternatively, the antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM-1) consisting of the anti-HER2 mAb trastuzumab linked to the cytotoxic agent emtansine (DM-1), which enters and destroys the HER2-overexpressing cells by binding to tubulin, was successful in patients with advanced breast cancer (13, 14) . Trastuzumab and pertuzumab induce antibody-dependent cell-mediated cytotoxicity (ADCC) and/or cell death of tumor cells by inhibition of HER2 signaling (15) (16) (17) . ADCC is mediated by activating Fcγ-receptor (FcγR) bearing myeloid cells as well as by natural killer (NK) cells or γδ T lymphocytes (10, (18) (19) (20) . Regarding γδ T cells, Capietto and colleagues recently reported that adoptive transfer of human Vγ9Vδ2-expressing γδ T lymphocytes from healthy donors (HDs) together with trastuzumab reduced growth of HER2-expressing breast cancer tumors grafted into immunocompromised mice. In their study, γδ T cells bound to mAb-labeled breast cancer tumors via FcγRIII (CD16) and thereby exerted ADCC (21) .
Differential clinical responses toward therapeutic antibodies such as trastuzumab or rituximab related to polymorphisms in FCGRIIA and FCGRIIIA genes have promoted the development of Fc engineered antibodies, which improve cellular cytotoxicity Abbreviations: BrHPP, bromohydrin-pyrophosphate; bsAb, bispecific antibodies; HD, healthy donors; HER2, human epidermal growth factor receptor 2; mAb, monoclonal antibodies; n-BP, nitrogen-containing bisphosphonates; OC, ovarian cancer; PAg, phosphorylated antigen; PBL, peripheral blood lymphocytes; pCR, pathological complete response; PDAC, pancreatic ductal adenocarcinoma; RTCA, real-time cell analyzer; TCR, T cell receptor; TIL, tumor-infiltrating lymphocytes. against tumors (16, 17, 22, 23) . Besides, enhanced cytotoxicity was also obtained with bispecific antibodies (bsAb), which allow redirecting of distinct effector cell populations including T lymphocytes to the tumor-site (24) . The development of bsAb recruiting T cells has been successfully introduced into clinical application for blinatumomab and catumaxomab for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia and malignant ascites, respectively (25) (26) (27) . Targeting solid tumors with bsAb is more complex and is under investigation (28, 29) . bsAb also offer the ability to selectively trigger a distinct activating FcγR with high affinity and allow recruitment of FcγR expressing effector cells. For example, bispecific [HER2xCD16] antibodies retargeting NK cells to tumors have proven efficacy (30) (31) (32) .
γδ T lymphocytes are attractive effector cells for bsAb based on their HLA-independent recognition of antigens, their capacity to present antigens to αβ T cells and not to induce a severe graft-versus-host disease (33) (34) (35) (36) . Previously, we have shown the efficacy of bsAb, such as [HER2xCD3] and [(HER2)2xVγ9], which selectively target CD3-and/or Vγ9-expressing T cells to HER2-expressing pancreatic ductal adenocarcinoma (PDAC) cells. HER2 is overexpressed on tumor cells of patients with PDAC (37) . In particular, [(HER2)2xVγ9] selectively enhanced the cytotoxicity of Vγ9-expressing T cells from PDAC patients in vitro by inducing the release of perforin and granzyme B as well as in vivo in xenograft models of PDAC upon transfer of human γδ T cells (38) . These data are of great interest because PDAC is an extremely aggressive disease with poor prognosis and limited therapeutic options due to the resistance of PDAC to chemotherapy (39) . Similar to PDAC, ovarian cancer (OC) is also regarded as an aggressive malignancy with a characteristic immunosuppressive tumor microenvironment (40) . Ultimate recurrence of (serous) OC after surgery is often associated with poor prognosis and resistance against chemotherapy (41) . In this study, we focused on a bsAb in the tribody format, [(HER2)2xCD16], to redirect CD16-expressing γδ T cells in addition to NK cells to lyse HER2-expressing tumor cells. For this purpose, γδ T cells and NK cells were used for cytotoxity assays, and applied either as peripheral blood lymphocytes (PBL) or tumor-infiltrating lymphocytes (TIL), as purified cells isolated out of PBL or TIL (freshly isolated) or as short-term in vitro expanded cells (suitable for adoptive cell transfer). The potential of tribody [(HER2)2xCD16] to enhance the cytotoxicity of these cells against allogeneic cancer cell lines and autologous primary OC cells was compared to the cytotoxic activity mediated by trastuzumab.
MaTerials anD MeThODs

Patient cohorts
Leukocyte concentrates from healthy adult blood donors were obtained from the Department of Transfusion Medicine of the University Hospital Schleswig-Holstein (UKSH) in Kiel, Germany. Heparinized blood was drawn from healthy donors (HDs) of the Institute of Immunology [UKSH, ChristianAlbrechts University (CAU)], whereas blood from patients was obtained from the Department of General and Thoracic Surgery or the Clinic of Gynecology and Obstetrics, both of the UKSH in Kiel. In accordance with the Declaration of Helsinki, written informed consent was obtained from all donors, and the research was approved by the relevant institutional review boards (ethic committee of the Medical Faculty of the CAU to Kiel, code number: D405/10, D403/14, D404/14). Twenty-four patients with histologically verified PDAC (10 females, age 67.2 ± 12.1 years; 14 males, age 66.6 ± 6.9 years, stage pT1-4, pN0-1, L0-1, V0-1Pn 0-1, R0-1) were enrolled. None of the patients had been treated with chemo-or radio-therapy prior to this investigation. Moreover, 20 patients (7 females, age 72.3 ± 6.5 years; 13 males, age 67.2 ± 7.5 years) with other (cancer) diseases were included as follows: 3x papillary carcinoma, pancreaticobiliary type, 3x (multi-cystic) serous cystadenoma of the pancreas, 3x neuroendocrine papilla carcinoma, 2x cholangiocarcinoma, 2x bile duct carcinoma, 2x gastrointestinal carcinoma, 1x tubular adenocarcinoma with high-grade epithelial dysplasia, 1x lymph nodes in the pancreatic head, 1x jejunum metastasis, 1x hepatocellular carcinoma, 1x B cell Non-Hodgkin lymphoma. For functional assays, one patient with advanced stage of breast cancer (age 55 years, stage IIIB, high grading) and one patient with OC (OC1, age 60, high-grade serous, stage IIIC) at first diagnosis shortly after surgery and before chemotherapy were additionally enrolled (code number: AZ A157/11, AZ B3277/10). From another OC patient (OC11, age 52, high-grade serous, stage IIIC) tumor material was obtained after exploratory laparotomy before chemotherapy and blood before and after neoadjuvant chemotherapy with carboplatin/paclitaxel (4x, q3w) plus bevacizumab administered at the second cycle. The adjuvant therapy was followed by three further cycles with carboplatin/ paclitaxel (3x, q3w). For flow cytometric analysis, PBL and TIL of 15 patients with advanced OC [age 56 ± 13 years, FIGO-stage IB-IVB (serous or mucinous carcinomas)] were enrolled (AZ B3277/10).
isolation and In Vitro culture of lymphocyte Populations
Peripheral blood lymphocytes were isolated from the leukocyte concentrates, from heparinized blood, or from EDTA blood by Ficoll-Hypaque (Biochrom, Berlin) density gradient centrifugation. To separate freshly isolated γδ T cells or NK cells, negative selection kits [T cell receptor (TCR) γδ + T Cell Isolation Kit or NK cell Isolation Kit, Miltenyi Biotec, Bergisch Gladbach], according to the manufacturer's instructions were used.
To establish short-term γδ T cell lines, PBL were cultured in RPMI 1640 supplemented with 2 mM l-glutamine, 25 mM Hepes, 100 U/mL penicillin, 100 µg/mL streptomycin, 10% FCS (complete medium), and stimulated with their selective antigens 300 nM phosphorylated antigen (PAg) Bromohydrinpyrophoshate [(BrHPP); kindly provided by Innate Pharma, Marseille, France] or 5 µM of nitrogen-containing bisphosphonates (n-BP) zoledronic acid (Novartis, Basel, Switzerland). 50 U/mL rIL-2 (Novartis) was added every 2 days over a culture period of 14-21 days. After 2-3 weeks, most γδ T cell lines had a purity of >95% Vδ2 γδ T cells. γδ T cells with a purity of <98% were labeled with anti-TCRαβ mAb clone IP26 (Biolegend, San Diego, CA, USA) and subjected to magnetic separation in order to deplete remaining αβ T cells. Magnetically depleted γδ T cells as well as γδ T cells of donors of whom we initially received only 1 mL blood with a low percentage of γδ T cells were re-stimulated to ensure large-scale expansion of pure γδ T cell lines as previously described (42, 43) .
separation of Tumor-infiltrating lymphocytes and Primary Tumor cells
Tumors from patients with advanced OC removed during surgery were dissected in tumor tissues by the pathologist of the UKSH. Tumor tissue was washed in 10 cm dishes with PBS to remove blood debris. Subsequently, the tumor tissue was minced into approximately 1 mm 3 pieces and digested in 5-10 mL PBS with enzymes A, K, and R of the Tumor Dissociation Kit (Miltenyi Biotec) for 1 h at 37°C. Digested cell suspension was then passed through a 100 µm cell strainer (Falcon, BD Bioscience, Heidelberg), visually controlled by light microscopy and centrifuged at 481 g for 5 min. Cell pellet was resuspended in complete medium and cultured in 75 cm 2 culture flasks to establish primary tumor cell lines. TILs were isolated by Ficoll-Hypaque density gradient centrifugation. Polyploidy of primary tumor cells was analyzed by using the tricolor probe TERC (3q26)/MYC (8q24)/ SE 7 TC (Kreatech/Leica, #KBI-10704) for fluorescence in situ hybridization (FISH) as previously described (44) . Polyploidy was detected in 60-100% of cells in each investigated primary ovarian tumor sample which classified them together with a high expression of HER2 and epithelial cell adhesion molecule as cancer cells. (45) . Briefly, Lenti-X™ 293T-cells were co-transfected with corresponding expression vectors coding for light or heavy chain derivatives of the tribodies using the calcium phosphate technique including 5 mM chloroquine. Heterodimeric tribody molecules composed of a light chain and a heavy chain tagged with a C-terminal hexahistidine motif were purified from supernatant by two successive steps of affinity chromatography using CaptureSelect Fab kappa affinity matrix (BAC B.V., Naarden, The Netherlands) and nickel-nitrilotriacetic acid agarose beads (Qiagen, Hilden, Germany) as described earlier (38, 45) . Purity and integrity of bsAb were verified by capillary electrophoresis using an Experion™ Automated Electrophoresis System (Bio-Rad, München). Cr-release assay with titrated numbers of γδ T effector cells supplemented with 12.5 U/mL IL-2 as described elsewhere (38) . To investigate possible increase of cytotoxic activity, cells were treated with 300 nM BrHPP, the indicated concentrations of trastuzumab, tribody [(HER2)2xCD16], or tribody [(CD20)2xCD16] as a control construct. Supernatants were measured in a MicroBeta Trilux β-counter (Perkin Elmer). Specific lysis was calculated as [(cpmtest − cpmspontaneous)/(cpmmax − cpmspontaneous)] × 100, where spontaneous release was determined in medium only and maximal release in Triton-X-100-lysed target cells. Spontaneous release did not exceed 15% of the maximal release.
Tumor cell lines
Flow cytometry
real-Time cell analyzer (rTca)
As an alternative assay to measure cytotoxicity against adherent cells a real-time cell analyzer (RTCA, xCELLigence, ACEA, San Diego, CA, USA) was used as described elsewhere (35, 43, 46) . Briefly, 5,000-15,000 adherent tumor cells/well were added to 96-well micro-E-plate in complete medium to monitor the impedance of the cells via electronic sensors every 5 min for up to 24 h. The impedance of the cells is expressed as an arbitrary unit called cell index (CI) which reflects changes in cellular parameters such as morphological changes (e.g., spreading, adherence), cell proliferation, and cell death. Since the initial adherence in different wells can differ slightly, the CI was normalized to 1 after having reached the linear growth phase and before the addition of constructs, substances, or suspended cells. Then, trastuzumab or tribody [(HER2)2xCD16] and corresponding control constructs were added in the previously titrated optimal concentrations. Thereafter, PBL, freshly isolated γδ T cells or NK cells, or short-term activated γδ T cells together with the indicated 12.5-50 U/mL IL-2 were added to the RTCA-single plate (SP) assay (xCELLigence). Where indicated, short-term activated Vδ2 γδ T cells were stimulated with 300 nM BrHPP. When effector cells induced lysis of the tumor cells, the loss of impedance of tumor cells shown as decrease of the normalized CI was analyzed. As positive control for killing, tumor cells were treated with a final concentration of 1% Triton X-100. For the precise analysis of cytotoxicity, the cells were monitored every minute for the indicated time points.
cD107a-Degranulation assay and elisa
Twenty thousand PDAC cells in 96-well microtiter plates (Nunc, Wiesbaden) were cultured overnight. Medium or 1 µg/mL [(HER2)2xCD16] or control constructs with or without 300 nM BrHPP together with short-term activated γδ T cells (E/T ratio: 12.5:1) supplemented with 12.5 U/mL rIL-2 were added after 24 h. For CD107a-assay, 10 µL FITC-labeled anti-human CD107a mAb clone H4A3 (50 µg/mL, Biolegend) was added directly, whereas 3 µM monensin was added 1 h after co-culturing the cells. After additional 3 h, γδ T cells were stained with PE-labeled anti-TCRγδ mAb, and analyzed by flow cytometry.
For assessment of granzyme B with ELISA, cell culture supernatants of duplicates were collected after 4 h and stored at −20°C until use. Human granzyme B was measured by a sensitive sandwich ELISA following the procedures outlined by the manufacturer (R&D System, Wiesbaden, Germany).
statistical analysis
The statistical analysis was assessed by Wilcoxon rank sum test or ANOVA using Graph Pad Prism (Graph Pad Software, Inc., La Jolla, CA, USA). Data from at least three independent biological replicates were used to test for normal distribution with the Shapiro-Wilk test (Graph pad Prism) followed by a parametrically t test using Microsoft Excel. All statistical tests were two-sided and the level of significance was set at 5%. In further experiments, we asked for possible reasons for this and strategies to further enhance cytotoxicity by cells of the innate and innate-like immunity.
characterization of immune cells of Tumor Patients Which can Be engaged by Trastuzumab
Besides varying direct effects of trastuzumab on the different tumor cells, one possible additional explanation for the weak lysis of PDAC cell lines by PBL from cancer patients is our observation of a significantly decreased CD16 expression on Vδ2-positive γδ T cells within the PBL of PDAC patients (Figure 2A , right panel), in contrast to TCR γδ-negative NK cells (Figure 2A, left panel) , which was not present in age-matched HDs or patients with other different (cancer) diseases (shortly before surgery, listed in Section "Materials and Methods") (Figure 2A) . Of note expression of other activating Fcγ receptors, i.e., Fcγ RI (CD64) and Fcγ RIIA (CD32A) on γδ T cells were not observed (data not shown). Independent of our in vitro assay studies with PBL and tumor cells, a low number of CD16-expressing immune cells within the tumors can be responsible for a reduced response toward trastuzumab in tumor patients. Thus, we exemplarily analyzed fresh tumor material of advanced OC patients, where the majority of the analyzed tumors expressed HER2 and compared the distribution of NK cells and γδ T cells within the tumors and the blood of these patients ( Figure 2B ). Interestingly, a significantly reduced number of NK-and γδ-T cells within TIL compared to PBL was observed ( Figure 2B ).
Bispecific antibody as an alternative to Trastuzumab
As trastuzumab did not optimally inhibit tumor cell proliferation, we employed a bispecific antibody in the tribody format ( Figure 3A) . [(HER2)2xCD16] consists of a CD16 Fab fragment and two single chain fragments variable (scFv), which were derived from trastuzumab variable regions and which were genetically fused with a flexible linker to the CH1-or CL-domains of the CD16 Fab. [(HER2)2xCD16] was transiently expressed in Lenti-X 293 T cells, purified, and analyzed by capillary electrophoresis ( Figure 3B ). Tribody [(HER2)2xCD16] specifically bound HER2-positive tumor cells ( Figure 3C ) and CD16-expressing NK cells as well as γδ T cells (Figure 3D ), but not antigen-negative cells such as Raji or αβ T cells (Figures 3C,D) . In addition, tribody [(HER2)2xCD89] was used as a control, which did not bind to CD89-negative NK cells, γδ-, or αβ-T cells ( Figure 3D) . The cytotoxic activity triggered by the tribody [(HER2)2xCD16] was initially analyzed at varying concentrations and varying effector to target cell ratios (E/T ratio) (data not shown and following Figures). We measured a saturating concentration of tribody [(HER2)2xCD16] between 0.1 and 1 µg/mL. In contrast, the saturating concentration of trastuzumab was 10 µg/mL. (Figure 6C, medium) . Similar to the γδ T cells within the PBL, we screened the CD16 expression on all established short-term expanded γδ T cells of HD (n = 43) as well as of PDAC patients (n = 20) which were used in different experiments in this studies ( Figure S3 in Supplementary Material). In general, we observed a high variability in CD16 expression between 1 and 70% which drastically influenced the effectiveness of trastuzumab ( Figure S3 in Supplementary Material; Figure 6C ). Although we observed that the combination of trastuzumab and PAg BrHPP enhanced γδ T cellmediated killing of PancTu-I cells (Figure 6C, phosphoantigen) , the application of tribody [(HER2)2xCD16] was more potent in enhancing γδ T cell-mediated killing (Figure 6D , medium) than trastuzumab ( Figure 6C , medium) presumably due to the higher CD16 binding affinity. Interestingly, the combination of tribody [(HER2)2xCD16] and BrHPP enhanced the cytotoxic activity of γδ T cells from PDAC patients more prominent than γδ T cells from HDs (Figure 6D, phosphoantigen) . This can be explained by the lower CD16 expression on γδ T cell lines of PDAC patients ( Figure 6A) . Importantly, it demonstrates the effectiveness of tribody [(HER2)2xCD16] on low CD16-expressing cells.
In another assay with additional short-term expanded γδ T cell lines of three different donors as effector cells and HER2-expressing PancTu-I cells, we analyzed in parallel HER2-negative, CD20-positive Raji tumor cell line as target cells to prove specificity 
γδ TCR-negative cells were calculated within lymphocytes (R1; FSC/SSC) by pan T cell receptor (TCR) γδ-negative and CD16-positive expression (W1; I). CD16
+ TCR γδ (Vδ2)-positive T cells were determined within lymphocytes (R1; FSC/SSC) by CD16-positive as well as by pan TCR γδ-positive (I) and Vδ2-positive (II) cells. For precise CD16 expression on Vδ2-positive T cells, an additional gate (R2; II) was set and the expression was calculated in the logical gate of "R1 AND R2" (W2; III). In parallel, CD3 expression of all analyzed γδ T cells was determined (data not shown). The relative percentage of CD16-expressing γδ T cell-negative cells [NK cells, (W1 within R1)] and TCR Vδ2 γδ-positive T cells (W2 within R1 and R2) were analyzed from PBL of age-matched HDs (HD, n = 24, 12 females, 12 males; age 65 ± 10 years), from PDAC patients (n = 24, 12 females, 12 males; age 64 ± 11 years), and from patients with other cancer diseases (n = 15, age 64 ± 11 years). Each symbol represents the data of one donor, and the thick bars represent the mean value of different experiments. Significances were performed by the Wilcoxon rank sum test and are shown as P value; *P < 0.05. (B) Gating strategy of NK cells and γδ T cells within PBL or TIL of one OC patient. NK cells were defined by CD3-negative and CD56
+ cells (W3) within R1 (FSC/SSC) and γδ T cells by CD3 + pan TCR γδ + cells (W4) within R1. The relative percentage of NK cells (n = 11; age 57 ± 10) is shown in "W3 within R1" and for γδ T cells (n = 15; age 56 ± 13) in "W4 within R1." Each symbol presents the data of one donor. Mean values of different experiments are indicated (thick bars). Significances were assessed by the Wilcoxon rank sum test and are shown as P value, *P < 0.05. Cr-release assay for PancTu-I cells were confirmed by the RTCA-assay (Figure 7) . Again, the tribody [(HER2)2xCD16] enhanced the γδ T cell-mediated cytotoxicity against PancTu-I cells at different E/T ratios more extensively than trastuzumab independent of whether shortterm expanded γδ T cells from PDAC patients (n = 7) or from HDs (n = 4) were used ( Figure 7A) . Similar to the results with PancTu-I cells, we observed that γδ T cell cytotoxicity against other HER2-expressing tumor cells such as established breast cancer cell line MCF-7 ( Figure 7B ) or autologous primary OC cells OC11 ( Figure 7C ) was increased. The lysis of the latter one was enhanced after addition of autologous short-term expanded γδ T cells isolated from TIL together with tribody [(HER2)2xCD16]. As expected, the control constructs had no cytolytic effect (data not shown). We observed no significant enhancement of γδ T cell cytotoxicity by the tribody [(HER2)2xCD16] compared to trastuzumab when we used a high E/T ratio and Panc89 cells as target cells, which were lysed more efficiently than other PDAC cells (e.g., PancTu-I-or Panc1 cells; Figure S5 
enhanced γδ T cell cytotoxicity against her2-expressing Tumor cells by Tribody [(her2) 2 xcD16] is Mediated by cytolytic granules
Besides the aspect that several PDAC cells are almost resistant to the CD95-or TRAILR-induced cell death, γδ T cells mainly mediate their cytotoxic activity through the release of cytolytic granules (47) . As shown in Figure 8 , the CD107a-degranulation assay revealed a significantly enhanced exocytosis after application of tribody [(HER2)2xCD16] to short-term expanded γδ T cells from HDs or PDAC patients co-cultured with PancTu-I cells which was accompanied by an increase in granzyme B release (Figures 8A,B) . Degranulation was per se higher after PAg-stimulation, but was further significantly enhanced after additional application tribody [(HER2)2xCD16] ( Figure 8A) . Interestingly, the intracellular content of granzyme B was not influenced by the treatment with tribody [(HER2)2xCD16] suggesting a permanent intracellular production of granzyme B (Figure 8C ).
DiscUssiOn
In this study, the tribody [(HER2)2xCD16] efficiently enhanced the cytotoxic activity of NK cells and γδ T cells of healthy persons as well as of cancer patients against HER2-expressing tumor cells including breast-, pancreatic-, ovarian-, and esophageal cancer cells. While NK cells can be activated directly by tribody [(HER2)2xCD16], the addition of exogenous IL-2 as well as the TCR engagement is essential for inducing cytotoxicity in resting γδ T cells pointing to a pre-activation of γδ T cells by their selective antigens (e.g., PAg or n-BP) in vivo or an adoptive transfer of short-term activated γδ T cells together with the tribody as potential therapeutic strategies.
In contrast to trastuzumab, tribody [(HER2)2xCD16] enhanced the cytotoxic activity even of CD16 low-expressing γδ T cells of PDAC patients together with their selective antigens (e.g., PAg or nBP) and IL-2 against HER2-low-expressing PDAC cell lines. Interestingly, we observed a reduced number of NK cells within TIL of OC patients before surgery and chemotherapy which may explain the superiority of PBL compared to TIL (both from OC patients) against autologous tumor cells. An activation of γδ TIL of OC patient OC11 after neoadjuvant chemotherapy stimulated via PAg together with Th1 cytokine IL-2 and tribody [(HER2)2xCD16] efficiently increased lysis of autologous HER2-expressing primary OC cells (OC11) suggesting a compensation of the low number of NK cells within TIL by γδ T cell activation. In this context, our own additional data reveal that the absolute γδ T cell number in a cohort of 26 breast cancer patients receiving chemotherapy did not differ from the number before chemotherapy, in contrast to decreased NK cells and αβ T cell numbers (48) . Human epidermal growth factor receptor 2 can be overexpressed in advanced breast, gastric, colorectal, pancreatic, and OC cells (6) . In general, HER2-expressing tumors are regarded as biologically aggressive neoplasms frequently associated with chemo-resistance and poor clinical outcome. Therapy with humanized HER2 mAb targeting different members of the epidermal growth factor receptor (EGFR) family combined with cytostatic agents e.g., docetaxel and potentially tyrosine kinase inhibitors such as, e.g., lapatinib or neratanib/afatinib has clearly improved the outcome of patients with metastatic breast or gastric cancer (6, (10) (11) (12) . Trastuzumab as well as pertuzumab induce cell death in vitro by inhibiting the Ras-MAP-kinase-or PI3K/ Akt/mTOR pathway in tumors or ADCC (2, 49) . In neoadjuvant settings, trastuzumab and pertuzumab in combination with chemotherapy have been shown to improve pathological complete response (pCR) in early or locally advanced breast cancer. In adjuvant settings, trastuzumab with taxane-based chemotherapy is considered standard of care (2, 11, (50) (51) (52) (53) .
Combining trastuzumab with chemotherapy has been also described in a few clinical trials to significantly improve overall survival compared with chemotherapy alone in HER2-positive advanced gastric and in one clinical trial in metastatic pancreatic cancer (37, 54, 55) . In addition, several case reports described an effect of trastuzumab on HER2-expressing uterine serous and high-graded endometrioid tumors varying from complete response to stable disease for 11 months (56-58). However, single drug trastuzumab in HER2-overexpressing OC show only moderate activity (59) . Anti-HER2 monotherapy is currently not a standard therapy for OC patients. Several previously unpublished or ongoing phase I or II trial studies (https://clinicaltrials.gov/.) treated OC patients with either trastuzumab combined with chemotherapy (NCT00433407) or HER2 cytotoxic T-cell (CTL) peptide-based vaccine (NCT00194714) or anti-CD3xanti-HER2/ neu (HER2Bi) armed anti-CD3 activated T cells (aATC) plus low-dose aldesleukin and sargramostim (NCT02470559). The application of our tribody [(HER2)2xCD16] to OC patients could be an option to enhance avidity to HER2-expressing OC cells due to the format with the two HER2-binding sites as well as the possibility to target innate cells (NK cells) as well as cells linking innate and adaptive immunity (γδ T cells) instead of a polyclonal activation of all T cells after stimulation with anti-CD3.
In our studies, we observed a direct effect of trastuzumab on breast cancer cells MCF-7 in vitro and enhanced trastuzumabmediated lysis in the presence of PBL which mediate ADCC. In addition, we demonstrated an enhanced lysis of HER2-expressing tumor cells by the combination of trastuzumab and PBL in PDAC cell lines established from primary cells (stage G1-G3, e.g., PancTu-I and Panc1) as well as in OC cells such as cisplatinresistant SK-OV-3 cells and primary tumor cells OC1 and OC11.
Besides an initial existing resistance against anti-HER2 treatment, a further not completely understood problem seems to be an evolving secondary HER2-resistance. Several reasons are suggested as follows (6, + T cells in the tumor microenvironment which supports cytotoxic T cells, such as CD8 + αβ TCR + or γδ TCR + cells (5, 64, 65) . Novel strategies are in development aiming to achieve more effective and durable responses. An attempt to combat trastuzumab resistance was the development of the ADC trastuzumab emtansine (T-DM-1). The cytotoxic agent emtansine (DM-1), which destroys tumor cells by binding to tubulin, has been conjugated to trastuzumab which inhibits the PI3K signaling (13, 49 ). An improvement of progression-free and overall survival in heavily pretreated patients with advanced HER2
+ breast cancer and an acceptable toxicity profile has been demonstrated in phase III clinical trials (66, 67) . Ongoing trials evaluate the role of T-DM-1 in neoadjuvant treatment of HER2 + breast cancer (68) . In parallel, the development of further ADC such as SYD985 which are tested in ongoing phase I clinical trials, is enforced (49) .
Another possibility can be a Th1 cytokine-induced senescence in tumor cells (5, 64, 65) . The treatment of HER2-expressing breast cancer cells with Th1 cytokines, IFN-γ and TNF-α can cause oncogene inactivation of HER2 followed by a cell-cycle arrest of the tumor cells (5, 64) . Since IFN-γ/TNF-α treatment of patients is not advisable, HER2
+ breast cancer patients were treated with HER2-pulsed dendritic cells (DC) to restore depressed Th1 response which seems to be due to a functional and reversible cytokine shift (69). Datta et al. reported that a preserved anti-HER2 Th1 response was associated with pCR to neoadjuvant trastzumab application combined with chemotherapy (70) . In addition, the anti-HER2 DC vaccination was combined with anti-estrogen therapy which improved regional nodal immune response and pCR rate in patients with estrogen receptor + /HER2 + early breast cancer (71) . The % of specific lysis was calculated by comparing measured samples to control sample (green line) and maximal lysis (black line). Statistical analysis was performed by t test. Significances are shown as P value; *P < 0.05 and **P < 0.01. A very promising strategy to overcome certain limitations of mAb and above-mentioned HER2-resistance mechanisms may be the use of bsAb with an enhanced cytotoxic activity against tumor cells (24) . Sahied et al. designed bispecific minibodies targeting HER2 and CD16 which possess the advantages of a native IgG with respect to flexibility but in a different format. ] and (a) degranulation was analyzed by staining γδ T cells with anti-Vδ2 TCR and anti-CD107a monoclonal antibodies and then determining the median fluorescence intensity (MFI) of CD107a on Vδ2 TCR-expressing γδ T cells using flow cytometry or by (B) measuring the release of granzyme B in the supernatants using specific ELISAs or (c) the intracellular MFI of granzyme B using a flow cytometer after 4 h of co-culturing. Result ± SD of three donors is shown. Statistical analysis was performed by t test. Significance is presented as *P < 0.05 and **P < 0.01. aUThOr cOnTriBUTiOns HO, CK, MP, and DW performed the conception and the experimental design. The experiments, the analysis, and interpretation of the data and the preparation of the figures were done by HO, CK, MP, DG, and DW. SS and DB organized and provided the blood and tissue from PDAC and ovarian cancer patients, respectively. DK and MG provided the infrastrcuture for experimental set up and were helpful with the interpretation of the results. DW and HO wrote the manuscript. CK, MP, DK, SS, DB, DG, and MG revised the manuscript critically. All authors read and approved the final version of the manuscript.
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sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00814/ full#supplementary-material. FigUre s3 | Analysis of CD16 expression on short-term activated γδ T cells. For flow cytometric analysis, a gate was set on expanded Vδ2 γδ T cells with a purity of >95% (based on forward and side scatter properties to exclude dead cells) and on pan T cell receptor γδ-positive cells to determine the relative percentage of CD16-expressing Vδ2 γδ-positive T cells from healthy donors (n = 11) and from pancreatic ductal adenocarcinoma patients (n = 11). Each symbol presents the data of one donor, and the thick bars represent the mean value of different experiments. Statistical analysis was performed by t test. Significances are shown as P value; *P < 0.05. T cell lines at the indicated E/T ratio and substances were added as follows: without effector cells: complete medium (green line) or Triton-X-100 (black line); with effector cells and 12.5 IU/mL rIL-2 in medium (orange line), with 10 µg/mL trastuzumab (blue line), or with 1 µg/mL tribody [(HER2)2xCD16] (red line). The cell index was analyzed in 5 min steps over ~28-53 h and after normalization to 1 (after addition of PBL ± substances) in 1 min steps for >10 h. The average of three replicates with SD is represented for each tumor cell line with effector cells of one representative healthy donor (HD) in independent experiments (left panel). For validation, experiments were replicated several times under equal conditions using different Vγ9Vδ2 T cell lines of different donors in independent experiments (right panel). The cytotoxic capacity of Vγ9Vδ2 T cell lines against the indicated tumor cells calculated 4 h after addition of effector cells as % of specific lysis compared to control sample (green line) and maximal lysis (black line). Statistical analysis was performed by t test. Significances are shown as P value; **P < 0.01.
